C型慢性肝炎に対するインターフェロン治療による甲状腺機能障害と抗甲状腺自己抗体に関する検討

スポンサーリンク

概要

• 論文の詳細を見る

• We examined thyroid function in 358 patients with chronic hepatitis C undergoing interferon (IFN) therapy. Prevalence of antithyroglobulin (TgAb) and antiperoxidase (TPOAb) antibodies before therapy was 10.8% and 9.4%, respectively. Of the 358 patients, 15 (4.2%) developed a thyroid disorder 1-19 months after IFN therapy had commenced. Of these 15 patients, 13 exhibited hypothyroidism and were TgAb- or TPOAb-positive. The remaining 2 patients exhibited signs of hyperthyroidism and neither antibody was detected. High titers of TgAb and TPOAb were seen in patients with thyroid dysfunction compared with subclinical patients. All patients completed IFN therapy. Our findings show that high TgAb and TPOAb titers were predictive factors of thyroid dysfunction during IFN therapy.

著者

• 藤山 重俊

  Department of Gastroenterology and Hepatology, Kumamoto Shinto General Hospital

• 佐々木 裕

  Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences, Kumamoto University

• 原岡 克樹

  Department of Gastroenterology and Hepatology, Kumamoto Shinto General Hospital

• 森下 祐子

  Department of Gastroenterology and Hepatology, Kumamoto Shinto General Hospital

• 宮瀬 志保

  Department of Gastroenterology and Hepatology, Kumamoto Shinto General Hospital

• 大内田 義博

  Department of Gastroenterology and Hepatology, Kumamoto Shinto General Hospital

• 佐々木 裕

  Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences Kumamoto University

関連論文

• C型慢性肝炎に対するインターフェロン治療による甲状腺機能障害と抗甲状腺自己抗体に関する検討
• 1型高ウイルス量C型慢性肝炎に対するPEG-IFNα-2a+Ribavirin療法の治療成績―九州多施設共同研究―

スポンサーリンク